Meet Dr. GPCR Summit Partners
Twist Biopharma: Synthetic DNA Technologies Enable Fast and Responsive anti-GPCR Antibody Discovery and Optimization
Tuesday, 09/14/2021 @ 11:00 AM - EST
- Dr. Aaron K. Sato -
- CSO of Twist Biopharma -
- South San Francisco, California, USA -
Abstract
Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions. To enable the discovery of functional GPCR antibodies, we grafted a large number of GPCR-binding motifs into a focused antibody library. By incorporating these motifs into the antibody heavy chain CDR3, we developed our first generation GPCR library. Another approach mined the patented GPCR antibody sequences and used the sequence information to guide the design of another synthetic library. We demonstrate the utility of both libraries to discover potent functional antibodies against multiple GPCR targets. In this talk, Aaron Sato, CSO, Biopharma, will present several case studies on the use of this platform.
About Dr. Aaron K. Sato
Aaron is CSO and head of the Biopharma Vertical at Twist Bioscience. Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics for its clients. He also oversaw all discovery research functions both as Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma, Inc. He also held director-level positions at both Oncomed and Dyax Corp.
Dr. Aaron Sato on the web
Meet Dr. GPCR Summit Partners
